Dr.Reddy's SWOT Analysis, Competitors & USP

Dr.Reddy's Laboratories Ltd

Pharmaceuticals

Pharma and Healthcare

Life.  Research.  Hope

Strong vertically integrated portfolio of products, businesses & geographies

Active Pharmaceutical Ingredients (APIs), Custom Pharmaceutical Services (CPS), generics, biosimiler, differentiated formulations and News Chemical Entities (NCEs)

Healthcare professionals, retail outlets

Committed to providing affordable and innovative medicines for healthier lives

Below are the Strengths in the SWOT Analysis of Dr.Reddy's:

1. Company launched Peg-grafeelTM, an inexpensive variety of pegfilgrastim, used to fight infection in chemotherapy where company has sold some 1.5 million units of it.
2. Dowpharma/Chirotech acquisition provided proprietary chiral and biocatalysis technology
3.The acquisition of Beta pharma helped to introduce an array of generic products and show its presence in the European markets.
4. Has a strong workforce of over 15,000 employees

Here are the weaknesses in the Dr.Reddy's SWOT Analysis:

1. Discovery of drugs is a highly unpredictable business
2. Strict govt regulations and policies affects operational efficiency

Following are the Opportunities in Dr.Reddy's SWOT Analysis:

1. Leverage Biologics & Cytotoxic Infrastructure to deal with the need of Oncology Market
2.New partnerships to develop Biosimiler business
3. Develop cost effective ways of new drug development to improve business in emerging markets

The threats in the SWOT Analysis of Dr.Reddy's are as mentioned:

1.Preliminary investment for Drug discovery is very high

2. long gestational period for new drug development

3. increasingly stringent regulations for new drug development

Below are the top 4 competitors of Dr.Reddy's:

1. Sun pharma
2. Lupin
3. Cipla

4. Ranbaxy labs